ABIOMED (NASDAQ:ABMD) Upgraded to Strong-Buy at BidaskClub

BidaskClub upgraded shares of ABIOMED (NASDAQ:ABMD) from a buy rating to a strong-buy rating in a report published on Saturday, January 20th.

Several other analysts also recently commented on ABMD. Jefferies Group increased their price objective on ABIOMED from $175.00 to $208.00 and gave the stock a buy rating in a research note on Friday, September 29th. SunTrust Banks initiated coverage on ABIOMED in a research note on Friday, September 29th. They issued a buy rating and a $195.00 price objective for the company. Zacks Investment Research downgraded ABIOMED from a hold rating to a sell rating in a research note on Tuesday, October 10th. Leerink Swann reissued an outperform rating and issued a $200.00 price objective (up from $180.00) on shares of ABIOMED in a research note on Thursday, October 12th. Finally, BTIG Research downgraded ABIOMED from a buy rating to a neutral rating in a research note on Monday, October 16th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. ABIOMED currently has a consensus rating of Buy and a consensus price target of $263.86.

ABIOMED (NASDAQ ABMD) traded down $0.12 during mid-day trading on Friday, reaching $229.38. ABIOMED has a one year low of $107.33 and a one year high of $255.42. The company has a market cap of $10,140.00, a PE ratio of 115.85, a price-to-earnings-growth ratio of 3.04 and a beta of 0.36.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.20. The business had revenue of $154.00 million for the quarter, compared to the consensus estimate of $154.00 million. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. The firm’s revenue for the quarter was up 34.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.34 EPS. equities research analysts forecast that ABIOMED will post 2.39 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the company. Lord Abbett & CO. LLC grew its holdings in shares of ABIOMED by 282.5% in the second quarter. Lord Abbett & CO. LLC now owns 60,882 shares of the medical equipment provider’s stock valued at $8,724,000 after acquiring an additional 44,967 shares in the last quarter. State of Tennessee Treasury Department bought a new position in ABIOMED during the third quarter valued at $5,058,000. Janney Montgomery Scott LLC grew its holdings in ABIOMED by 46.3% during the third quarter. Janney Montgomery Scott LLC now owns 2,903 shares of the medical equipment provider’s stock valued at $489,000 after purchasing an additional 919 shares during the period. Hamilton Lane Advisors LLC grew its holdings in ABIOMED by 50.8% during the fourth quarter. Hamilton Lane Advisors LLC now owns 23,241 shares of the medical equipment provider’s stock valued at $4,356,000 after purchasing an additional 7,827 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in ABIOMED by 15.6% during the second quarter. PNC Financial Services Group Inc. now owns 9,067 shares of the medical equipment provider’s stock valued at $1,299,000 after purchasing an additional 1,225 shares during the period. 90.65% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://ledgergazette.com/2018/02/12/abiomed-abmd-upgraded-to-strong-buy-by-bidaskclub.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply